Compare Credo Technology Group Holding Ltd (CRDO) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Quest Diagnostics Inc — how do they compare? Credo Technology Group Holding Ltd trades at $216.19 (market cap $39.82B), while Quest Diagnostics Inc trades at $229.97 (market cap $25.48B). The key difference: Credo Technology Group Holding Ltd is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Quest Diagnostics Inc for 56 Days on average.
| CRDO | DGX | |
|---|---|---|
Market Cap | $39.82B | $25.48B |
Volume | 9,451,558 | 941,866 |
Sector | Technology | Health |
52-Week High | $302.52 | $247.45 |
52-Week Low | $87.81 | $173.49 |
Typical Hold Time | 22 Days | 56 Days |
Enterprise Value | $39.08B | $31.23B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $216.55, down 1.57% on the day, but maintains strong bullish momentum with triple-digit revenue growth driven by AI infrastructure demand. The stock shows robust fundamentals with 33.83% net margins and consistent earnings beats, though valuation metrics remain elevated with a P/E of 74.6. Technical indicators suggest bullish momentum with support at $204 and resistance at $222.
Outlook remains positive given explosive AI-driven growth and strong analyst support (87.5% buy ratings), but premium valuation and customer concentration present execution risks. The consensus price target of $267.33 implies 23% upside potential from current levels, supported by expanding optical product offerings and hyperscaler relationships.
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
